Toronto, Ontario – November 28, 2014 Theralase Technologies Inc. (“Theralase”) (TLT: TSXV) (TLTFF: OTC Link®) released its third quarter 2014 financial results today, demonstrating a decrease in revenue for the three month period ended September 30, 2014 of 57% and a decrease in revenue of 15% for the nine month period ended September 30, 2014, while making dramatic progress in both its patented next generation Therapeutic Laser Technology (“TLT”) division and its Photo Dynamic Therapy (“PDT”) anti-cancer division. Total revenue for the nine-month period ended September 30, 2014 decreased 15% from $1,165,215 to $994,473 for the same period in 2013. In Canada, revenue decreased 10% to $621,435 from $690,451, in the US, revenue remained flat to $234,167 from $234,128 and internationally revenue decreased 42% to $138,871 from $240,637. The decrease in revenue is mainly attributable to Theralase launching a new sales team and also prospective customers preferring to wait for … Read More

Toronto, Ontario – November 25, 2014 Theralase Technologies Inc. (“Theralase”) (TSXV: TLT) (TLTFF: OTCBB) announced today that it has released a video of the presentations conducted at the Theralase 2013 Annual General Meeting (“AGM”), held on November 14, 2014. The presentations were conducted by Theralase President and CEO, Roger Dumoulin-White and Dr. Lothar Lilge, Professor in the Department of Medical Biophysics University of Toronto and Senior Scientist, Ontario Cancer Institute, Princess Margaret Cancer Centre, University Health Network (“UHN”). Mr. Dumoulin-White presented the strategic vision for both the Therapeutic Laser Technology (“TLT”) division and the Photo Dynamic Therapy (“PDT”) anti-cancer division, while Dr. Lilge presented on the scientific and preclinical data supporting the recent advances in the PDT division. Both Mr. Dumoulin-White and Dr. Lilge were available to answer questions from the audience at the end of their presentations. Dr. Lothar Lilge PhD, Senior Scientist, Ontario Cancer Institute, Princess Margaret Cancer … Read More

Toronto, Ontario – November 12, 2014 Theralase Technologies Inc. (“Theralase”) (TSXV: TLT) (TLTFF: OTCBB) announced today that in new preclinical research, conducted at Princess Margaret Cancer Centre, University Health Network (“UHN”), that it has further validated its Photo Dynamic Compound’s (“PDCs”) ability to destroy a primary host tumour and even more importantly render the animal immune to a repeated exposure of the same cancer. In research conducted at UHN in March 2012, mice were injected with 350,000 colon cancer cells (mouse cell line CT26.CL25) to produce cancerous tumours that were allowed to grow to approximately five millimeters in size. These tumours were treated with an injection of one of Theralase’s lead PDCs and then illuminated by Near Infrared (“NIR”) light to activate the PDC. The vast majority of tumours were completely destroyed. These mice were closely monitored for 20 months post treatment, until November 2013, where they remained cancer free. … Read More

Toronto, Ontario – October 16, 2014 –Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC Link®) announced today that it has presented its latest research on the success of its Photo Dynamic Compounds (“PDCs”) in the destruction of cancer and bacteria. This research was presented at the 10th International Symposium on Photodynamic Therapy and Photodiagnosis in Clinical Practice, taking place in Brixen, Italy from October 14 to 18, 2014. Download the Research Cancer remains one of the top human conditions and effective minimal or non-invasive treatments with low side effects and high success rates are urgently needed. Photo Dynamic Therapy (“PDT”), the combination of a Photo Dynamic Compound (“PDC”) and a specific wavelength of light to produce cytotoxic (cell death) oxygen species, has been shown to be a promising avenue for cancer treatment. Theralase’s first preclinical presentation focused on the efficacy of its three lead PDCs to effectively destroy cancer cells … Read More

Toronto, Ontario – October 7, 2014 –Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC Link®) announced today that it has collaborated with Sigma-Aldrich Corporation’s (NASDAQ: SIAL) custom manufacturing services business unit SAFC® Commercial , in the manufacture of the Photo Dynamic Compounds (“PDCs”) being developed by Theralase for the destruction of cancer. Under the terms of the agreement, SAFC will develop the Standard Operating Procedures (“SOPs”) to manufacture initial quantities of each of Theralase’s four lead PDCs. Once Theralase selects the final lead PDC at the end of the fourth quarter 2014, SAFC will manufacture both a 100-gram pre-Good Manufacturing Practice (“pre-GMP”) batch and finally a 500-gram GMP batch of the PDC. This final 500-gram batch is intended to be suitable for final sterilization and packaging into individual patient doses for safety and efficacy evaluation through a Health Canada / FDA Phase I/IIa clinical trial, expected in early 2015. SAFC … Read More

Toronto, Ontario – September 24, 2014 –Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC Link®) announced today that it has filed a voluntary Annual Information Form (“AIF”) as part of its corporate strategy to become eligible for the registration of a base shelf prospectus as this term is defined in National Instruments 44-101 Short Form Prospectus Distributions and 44-102 Shelf Distributions. Roger Dumoulin-White, President and CEO of Theralase Inc. stated that, “As Theralase executes on its strategic initiatives of launching its next generation therapeutic laser system, the TLC-2000 in 4Q2014 and approval of an Investigational New Drug (“IND”) application for commencement of a Health Canada / FDA Phase I/IIa clinical trial to prove safety and efficacy in Non Muscle Invasive Bladder Cancer (“NMIBC”) in early 2015, Theralase would like to provide all investors the opportunity to invest in the Company and not be limited to accredited investors.” About Theralase Technologies … Read More

Toronto, Ontario / ACCESSWIRE / September 11, 2014 / To take advantage of the vastly improved business climate in Quebec, Theralase Technologies Inc. (“Theralase”) (TLT.V) (TLTFF: OTC Link(R)) announced today that it is partnering with JSS Medical Research Inc. (“JSS”), a Montreal based Contract Research Organization (“CRO”), to consult and provide guidance in the completion of a FDA / Health Canada Phase I/IIa clinical study. The clinical study planned for early 2015 will evaluate the safety and efficacy of Theralase’s innovative Photo Dynamic Therapy (“PDT”) platform in the destruction of bladder cancer. Theralase anticipates executing further agreements in the Quebec biotech sector worth several million dollars over the next 12 to 18 months. Bladder cancer is the fifth most common cancer (fourth for men, eighth for women), the most expensive cancer to treat, costing between $100k and $200k per patient and has the highest recurrence rate at 80%. In the … Read More

Toronto, Ontario / ACCESSWIRE / September 9, 2014 / Theralase Technologies Inc. (“Theralase”) (TLT.V) (TLTFF: OTC Link(R)) announced today that it has successfully launched its TLC-3000 multi wavelength laser system capable of activating its patented and patent pending Photo Dynamic Compounds (PDCs) for the destruction of cancer in an preclinical environment. This is the first commercial system on the market capable of effectively activating a 96 well plate of cancer cells with wavelengths in the visible to Near Infrared (NIR) spectrum using programmable energy levels. Intellectual protection for this system was recently applied for under a pending US patent. The new multi wavelength laser system has been delivered to Princess Margaret Cancer Centre, University Health Network (“UHN”) and to the University of Toledo for evaluation of safety and efficacy. Further developments and enhancements of this multi wavelength laser technology in 2015 will be to activate Theralase’s patented and patent pending … Read More

Toronto, Ontario / ACCESSWIRE / August 29, 2014 / Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF:OTC Link) released its second quarter 2014 financial results today, demonstrating a slight increase in revenue for the three month period ended June 30, 2014, edging up 1% year over year, while successfully advancing its patented next generation therapeutic laser and cancer destruction technologies. Total revenue for the six-month period ended June 30, 2014 increased 1% from $852,196 to $860,437 year over year. The net loss for the six-month period ended June 30, 2014 was $689,727 (including $64,304 of net non-cash expenses) compared to a net loss of $411,079 in the same period in 2013 (including $56,829 of net non-cash expenses). The net loss reflects the ongoing commitment of Theralase to invest in the next generation of therapeutic laser and cancer destruction technologies, from existing therapeutic laser sales. Sales and marketing expenses increased 27% from $237,221 … Read More

Toronto, Ontario – July 17, 2014 Theralase Technologies Inc. (“Theralase”) (TSXV: TLT) (TLTFF: OTC Link®) announced today that it has applied for a US patent for a multi-wavelength laser light source that is capable of safely and effectively activating its patented and patent pending Photo Dynamic Compounds (PDCs) in the destruction of cancer at various tissue depths. Theralase’s PDCs are able to be activated by laser wavelengths ranging from the visible spectrum to the Near Infrared (NIR) spectrum. This newly conceived multi-wavelength laser system is able to activate the PDCs from a few hundred microns (millionths of a meter) to ten centimeters in depth allowing oncologists the ability to target surface as well as deep cancerous tumors. Dr. Arkady Mandel, Chief Scientific Officer of Theralase stated, “The new multi-wavelength laser system combined with Theralase’s PDCs presents the first opportunity for an oncologist to be able to provide a fully “patient … Read More